Literature DB >> 6199232

Binding properties of a novel calcium channel activating dihydropyridine in monolayer cultures of beating myocytes.

P Bellemann.   

Abstract

Binding characteristics of [3H]BAY K 8644, a new class of pharmacologically potent compounds, the calcium channel activating dihydropyridines (DHP), were demonstrated in cultured myocardial cells. [3H]BAY K 8644 exhibited reversible and saturable binding to myocytes, and specific binding was Ca2+-dependent. The equilibrium dissociation constant, Kd, was 35.2 nM, and maximal binding capacity, Bmax, was 1.07 pmol/mg protein. Binding of the 3H-ligand was highly specific for various potently displacing DHP derivatives (either the calcium channel activating BAY K 8644, or the Ca2+ entry blockers of the nifedipine type) with inhibition constants (Ki values) in the nanomolar range. BAY K 8644, on the other hand, showed very low affinity to other receptors tested in brain and heart membranes. Displacement potency of BAY K 8644 correlated well with data of the functional pharmacology; e.g., the enhanced myocardial contractility. Results from competition studies using [3H]BAY K 8644 and [3H]nimodipine support the conclusion that both the channel activating and inhibiting DHP structures interact with the same specific receptor site that might be associated with the putative Ca2+-channel.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199232     DOI: 10.1016/0014-5793(84)80838-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  The positive inotropic action of the nifedipine analogue, Bay K 8644, in guinea-pig and rat isolated cardiac preparations.

Authors:  M Finet; T Godfraind; G Khoury
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

2.  Differential antagonism by Bay k 8644, a dihydropyridine calcium agonist, of the negative inotropic effects of nifedipine, verapamil, diltiazem and manganese ions in canine ventricular muscle.

Authors:  K Ishii; N Taira; T Yanagisawa
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

3.  Effects of Bay K 8644 on 45Ca uptake and efflux and on contraction in the rabbit aorta.

Authors:  Y J Dong; R M Wadsworth
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

4.  Bay K 8644 induce enhancement of K+ current in both single heart cell and smooth muscle cell.

Authors:  J F Renaud; G Bkaily; M Benabderrazik; D Jacques; N Sperelakis
Journal:  Mol Cell Biochem       Date:  1988 Mar-Apr       Impact factor: 3.396

5.  Proceedings of the British Pharmacological Society. Leeds, 12th-14th July 1989. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

6.  Effects of calcium channel antagonists and facilitators on beating of primary cultures of embryonic chick heart cells.

Authors:  L Patmore; G P Duncan
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

7.  The dihydropyridine derivative 202-791: interpretation of the effects of the racemate considering inverse agonistic enantiomers.

Authors:  M Damarowsky; H Lüllmann; U Ravens
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

8.  Stereoisomers of BAY K 8644 show opposite activities in the normal and ischaemic rat heart. A comparison with nifedipine.

Authors:  F T van Amsterdam; N C Punt; M Haas; M S van Amsterdam-Magnoni; J Zaagsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

9.  The positive inotropic dihydropyridine Bay K 8644 does not affect calcium sensitivity or calcium release of skinned cardiac fibres.

Authors:  G Thomas; R Gross; G Pfitzer; J C Rüegg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

10.  The calcium channel activator, Bay K 8644, enhances K+-evoked efflux of acetylcholine and noradrenaline from rat brain slices.

Authors:  D N Middlemiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.